anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Olopatadine
Trial phase: Phase 3
ATC code: R01AC08 | S01GX09
SMILES: CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 383
Group description: All subjects treated with olopatadine hydrochloride ophthalmic solution 0.1%
Eligibility criteria:
Inclusion Criteria:

Chinese ethnicity;
History of allergic conjunctivitis within the last 2 years;
Positive skin prick test or skin intradermal test documented by a lab report within 24 months of, or at the baseline visit;
Clinical diagnosis of allergic conjunctivitis with specific signs and symptoms;
Understand and sign an informed consent form;
Willing and able to make required study visits and follow study instructions, and comply with dosing study medication as instructed;
Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

Contraindications or hypersensitivity to study medications or their components;
Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal) in either eye;
Any ocular condition that could affect the study outcomes;
Presumed or actual ocular infection or history of ocular herpes in either eye;
Known history of retinal detachment, diabetic retinopathy, or any progressive retinal disease;
Willing and able to avoid the use of any other topical ocular medication(s) (including artificial tear products);
Any significant illness that could be expected to interfere with the study, particularly any autoimmune disease;
Intraocular surgery in either eye within 6 months, or ocular laser surgery in either eye within 3 months, or anticipation of ocular surgery during the study; ocular trauma in either eye within 3 months of baseline visit;
Clinically relevant recent (within 6 months of baseline visit) history of or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune disease and other relevant systemic diseases that would preclude the safe administration of a topical antihistamine/mast cell stabilizer in the opinion of the Investigator;
Use of systemic medication(s) on a chronic dosing regimen for less than 1 month or have changed dosage within the month prior to baseline visit;
Use of any disallowed medication (topical, topical ophthalmic, systemic and/or injectable) during the period indicated prior to baseline visit. These medications are also not allowed during the study. Disallowed medications include all anti-allergy therapies including those contained in prescription or over-the-counter sleeping aids;
Use of cold compresses on the eyes during the course of the study;
Cannot be dosed in both eyes;
Cannot avoid contact lens wear during the course of the study;
Therapy with another investigational agent within 30 days of baseline visit, or during the study;
Women of childbearing potential who are pregnant, intend to become pregnant during the study period, breast-feeding, or not using adequate birth control methods;
Other protocol-specified exclusion criteria may apply.
Intervention: Sarecycline
Trial phase: Phase 3
ATC code: J01AA14 | J01AA20
SMILES: [H][C@@]12Cc3c(CN(C)OC)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 513
Group description: Sarecycline tablets, 1.5 mg/kg/day, taken orally once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Signed informed consent or assent form
Male/female, 9 to 45 years of age, inclusive
Body weight between 33 and 136 kg, inclusive
Facial acne vulgaris with:
20-50 inflammatory lesions (papules, pustules and nodules)
30-100 noninflammatory lesions (open and closed comedones)
No more than 2 nodules
Investigator's Global Assessment (IGA) score of moderate (3) or severe (4)
Negative urine pregnancy test at baseline - females of childbearing potential
Agrees to use an effective method of contraception throughout the study
Refrain from use of any other acne medications and medicated cleansers, and avoid excessive sun exposure and tanning booths for duration of study
Able to fulfill the requirements of protocol, indicated willingness to participate in the study and agrees to all study procedures (including mandatory photography) by providing written informed consent/assent and an authorization to disclose protected health information (PHI).

Exclusion Criteria:

Has a dermatological condition of the face that could interfere with the clinical evaluations
Has a history of any of the following:
Allergy to tetracycline-class antibiotics or to any ingredient in the study drug
Pseudomembranous colitis or antibiotic-associated colitis
Treated for any type of cancer within the last 6 months
Has known resistance to other tetracyclines
Has receive any of the following treatments within 12 weeks of screening:
Systemic retinoids
Systemic corticosteroids
Androgens/anti-androgenic therapy (eg, anabolic steroids, spironolactone)
Non-medicated procedures for the treatment of acne (eg, laser, light or ThermaClear)
Has used any acne affecting treatment without an appropriate washout period
Has initiated hormonal contraceptive use within 12 weeks prior to screening or plans to initiate or switch hormonal contraceptive products during the study period
Is pregnant, lactating or planning a pregnancy during the study period
Has any other disorder causing hyperandrogenism including, but not limited to polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital adrenal hyperplasia
Has drug-induced acne
Has significant intercurrent illness, psychiatric disposition or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study
Is currently participating, or has participated within 30 days prior to the screening period in an investigational drug or device study
Has previously participated in any clinical trial involving the use of sarecycline
Is judged by the Investigator to be unsuitable for any reason.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: 50 mL normal saline solution

Normal saline solution: 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
Eligibility criteria:
Inclusion Criteria:

Adult (≥ 21 years)
Coronary artery bypass grafting (CABG) with or without concomitant valve procedures
EuroSCORE II > 1.5%

Exclusion Criteria:

Current thiamine supplementation
Known allergy to thiamine
Competing indication for thiamine administration as judged by the clinical team (e.g., alcoholic)
Research-protected populations (pregnant women, prisoners, the intellectually disabled)
Emergent or salvage CABG (as defined by the Society of Thoracic Surgeons)
Off-pump surgery (i.e. surgery without cardiopulmonary bypass)
Intervention: Victoza
Trial phase: Not Applicable
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects

Liraglutide: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects between the ages of 18-70
Subjects with Type 2 Diabetes Mellitus (T2DM)
Drug naïve or on stable dose (more than 3 months) of metformin with or without sulfonylurea
Have an HbA1c levels ≥7.0% and <10.0%
Stable weight (± 3 lbs) over the preceding 3 months

Exclusion Criteria:

Subjects taking drugs known to affect glucose metabolism (other than metformin) will be excluded.
Individuals with evidence of proliferative diabetic retinopathy or plasma creatinine >1.4 females or >1.5 males or estimated Glomerular Filtration Rate (eGFR)< 60 ml/min.172m2 will be excluded
Unstable body weight (change of greater than ±3 lbs over the preceding 3 months)
Participates in excessively heavy exercise program
Intervention: AQX-1125
Trial phase: Phase 2
SMILES: C=C1CC[C@H]2[C@H](CN)[C@@H]([C@@]3(C)CC[C@H](O)C[C@@H]3CO)CC[C@]12C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: 1 x AQX-1125 Capsule daily

AQX-1125: Synthetic SHIP1 activator
Eligibility criteria:
Inclusion Criteria:

Male or female aged from 18 to 65 years old
Confirmed clinical diagnosis of active atopic dermatitis (AD) according to the Hanifin and Rajka criteria
At least a 6 months history of atopic dermatitis.
Body Surface Area (BSA) covered with atopic dermatitis of 1% or more
Mild or moderate atopic dermatitis (IGA score of 2 or 3).
TLSS of 5 or more at Day 0.
Subject must use a non-medicated emollient daily for at least (≥) 7 days prior to Day 0 and should continue using that same emollient, at the same frequency, throughout the study.

Exclusion Criteria:

Female subject who is pregnant or breast-feeding
Unstable or clinically infected atopic dermatitis
Intervention: Roblitinib
Trial phase: Phase 1 | Phase 2
SMILES: COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Participants received single agent FGF401 50 mg while fasted
Eligibility criteria:
Inclusion Criteria:

ECOG Performance Status ≤ 1
Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401 single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II, Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF401 in combination with PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment

Exclusion Criteria:

Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR inhibitor.
Symptomatic CNS metastases which are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.

Patient having out of range laboratory values defined as:

Hematology Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3
Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT > 3 x ULN Serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 45 mL/min
Coagulation: PT > 4 seconds more than ULN or INR > 1.7
Pregnant or nursing (lactating) women.

Other protocol-defined Inclusion/Exclusion criteria may apply.
Intervention: Roblitinib
Trial phase: Phase 1 | Phase 2
SMILES: COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants received single agent FGF401 80 mg while fed
Eligibility criteria:
Inclusion Criteria:

ECOG Performance Status ≤ 1
Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401 single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II, Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF401 in combination with PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment

Exclusion Criteria:

Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR inhibitor.
Symptomatic CNS metastases which are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.

Patient having out of range laboratory values defined as:

Hematology Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3
Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT > 3 x ULN Serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 45 mL/min
Coagulation: PT > 4 seconds more than ULN or INR > 1.7
Pregnant or nursing (lactating) women.

Other protocol-defined Inclusion/Exclusion criteria may apply.
Intervention: CID 12303048
Trial phase: Phase 1
ATC code: S03AA04
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)C(O)C(O)C(O)C(O)CO
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 9
Group description: All subjects received a bath twice a week with 2% CHG bathing cloths. The baths were followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team monitored the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels were monitored for associated adverse events and accumulation.

Chlorhexidine gluconate: Bi-weekly chlorhexidine baths
Eligibility criteria:
Inclusion criteria.

Greater than/equal to 36 weeks PMA (gestational age + chronological age)
Less than/equal to 48 weeks PMA (gestational age + chronological age)
Greater than/equal to 3 days of age
Existing or soon to be placed, peripheral or surgical CVC
Permission to participate in trial by attending physician
Parent or legal guardian informed consent to participate in the trial

Exclusion criteria.

• Infant with a large open lesion or severe skin condition (i.e., Myelomeningocele, Gastroschisis, lymphatic malformation, open chest, ostomies and/or mucus fistulas or Icthyosis)
Infants with active seizure disorders
Infants with Hypoxic Ischemic Encephalopathy
Infants with severe multi-system organ failure or Liver failure as defined by documentation of abnormal liver function tests: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) Gamma-glutamyltransferase (GGT) and L-lactate dehydrogenase (LD).
Infant with renal impairment as defined by: documented serum Creatinine greater than 0.7, renal disorders (renal agenesis, polycystic kidney disease, dysplastic kidneys, acute renal injury).
Infants deemed clinically unstable by their physician such as patients that are extremely fragile and wouldn't tolerate the stimulation of the bathing process or those infants being considered for withdrawal of care.
Intervention: Tranexamic acid
Trial phase: Not Applicable
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Tranexamic Acid
Eligibility criteria:
Inclusion Criteria:

Individuals with osteoarthritis who indicated for primary TKA.

Exclusion Criteria:

Previous history of ceberovascular diseases
Previous history of myocardial infarction
Candidates for bilateral TKA
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Normal saline
Eligibility criteria:
Inclusion Criteria:

Individuals with osteoarthritis who indicated for primary TKA.

Exclusion Criteria:

Previous history of ceberovascular diseases
Previous history of myocardial infarction
Candidates for bilateral TKA
Intervention: Methylphenidate
Trial phase: Phase 1
ATC code: N06BA04 | N06BA11 | N06BA15
SMILES: COC(=O)C(c1ccccc1)C1CCCCN1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery

Methylphenidate HCl: Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
Eligibility criteria:
Inclusion Criteria:

Male or female, 18 to 65 years of age
ASA I or II
Capable and willing to consent
Participants literate in English language

Exclusion Criteria:

ADHD with current use of methylphenidate
Hypersensitivity to methylphenidate
ASA III, IV or V
Patients with severe visual or auditory disorder
Illiteracy
Presence of a clinically diagnosed anxiety, agitation, major psychiatric condition such as bipolar disorder, uncontrolled major depression, schizophrenia
Tics or Tourette's syndrome
Glaucoma
Hypertension, history of atrial arrhythmias (atrial fibrillation, atrial flutter), myocardial infarction
Taking or have taken within the past 14 days a monoamine oxidase inhibitor or MAOI (Selegiline)
Subjects who have participated or are currently participating in a clinical trial of an investigational drug within 30 days prior to surgery
Any condition, which in the opinion of the investigator would make subject ineligible for participation in the study such as history of unstable cardiovascular, pulmonary, renal, hepatic, neurologic (seizures), hematologic or endocrine abnormality (hyperthyroidism, unstable Diabetes type I/II)
Intervention: Clopidogrel
Trial phase: Not Applicable
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 502
Group description: taking plavix less than 12 months
Eligibility criteria:
Inclusion Criteria:

post stent ( lesion more than 70% and vessel more than 2.25 mm )

Exclusion Criteria:

allergy to acetylsalicylic acid or clopidogrel,
planned surgery within 24 months of percutaneous coronary intervention unless the dual antiplatelet therapy could be maintained throughout the perisurgical period
history of bleeding diathesis
major surgery within 15 days
active bleeding
previous stroke in the past 6 months
concomitant or foreseeable need for oral anticoagulation therapy
pregnancy, life expectancy <24 months, participation in another trial
inability to provide informed consent
Intervention: Clopidogrel
Trial phase: Not Applicable
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 508
Group description: taking plavix more than 12 months
Eligibility criteria:
Inclusion Criteria:

post stent ( lesion more than 70% and vessel more than 2.25 mm )

Exclusion Criteria:

allergy to acetylsalicylic acid or clopidogrel,
planned surgery within 24 months of percutaneous coronary intervention unless the dual antiplatelet therapy could be maintained throughout the perisurgical period
history of bleeding diathesis
major surgery within 15 days
active bleeding
previous stroke in the past 6 months
concomitant or foreseeable need for oral anticoagulation therapy
pregnancy, life expectancy <24 months, participation in another trial
inability to provide informed consent
Intervention: Kenalog
Trial phase: Phase 3
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: 15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.

Triamcinolone Acetonide: topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
Eligibility criteria:
Inclusion Criteria:

Patients presented with painful oral lichen planus lesions
Free of any visible oral lesions other than oral lichen planus
Free of any systemic diseases

Exclusion Criteria:

Topical treatment or systemic therapy of OLP for one month before starting the study
Pregnant or breast feeding women
Smokers
Use of corticosteroids or other immunosuppressive drugs
Intervention: Navamepent
Trial phase: Phase 2
SMILES: C#CCC(O)C=CC=CC#CC(O)CCCC(=O)OC(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 256
Group description: topical eye drops

RX-10045: topical therapy
Eligibility criteria:
Inclusion Criteria:

Unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation in the capsular bag.

Exclusion Criteria:

Any additional surgical procedures at the time of the cataract surgery
Refractive surgery in the study eye within the past 2 years
History or presence of noninfectious inflammatory ocular disease (e.g., episcleritis, scleritis, uveitis) in either eye
Intraocular pressure of > 21 mm Hg in either eye
Proliferative or severe nonproliferative diabetic retinopathy in either eye
Neovascular/wet age-related macular degeneration in either eye
Intervention: Epicatechin
Trial phase: Phase 1
SMILES: Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 4
Group description: 4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally

(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
Eligibility criteria:
Inclusion Criteria:

Healthy or pre-diabetic based on medical history
Male or female
Must be 21 to 75 years of age (inclusive)
Able to give informed consent to the procedures
If female, must be either postmenopausal or test negative for pregnancy at screening and on the day of the procedure. Women on estrogen therapy will be included.
If of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study
Medication use stable for 4 weeks
Body Mass Index (BMI) > 27 kg/m^2
Definition of pre-diabetes: impaired fasting glucose (IFG, fasting glucose = 100-125 mg/dL) and elevated HbA1c (5.7-6.4%), each in the absence of other risk factors for diabetes

Exclusion Criteria:

Type 2 diabetes
Pregnancy
Younger than 21 or older than 75 years of age
Clinically significant abnormalities in liver or kidney function (>3x ULN), determined in the last 6 months by a certified clinical laboratory
Recent MI or stroke (within 6 months of screening)
Blood pressure (BP) >160 mmHg Systolic and >100 mmHg Diastolic
Medications - thiazolidinediones, any steroids, anti-depressants, weight loss drugs
Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism